{"id":"https://openalex.org/W3096239751","doi":"https://doi.org/10.1182/blood-2020-143253","title":"Clinical Features, Treatments and Outcomes of HIV-Associated Diffuse Large B-Cell Lymphoma: A Single-Center Experience","display_name":"Clinical Features, Treatments and Outcomes of HIV-Associated Diffuse Large B-Cell Lymphoma: A Single-Center Experience","publication_year":2020,"publication_date":"2020-11-04","ids":{"openalex":"https://openalex.org/W3096239751","doi":"https://doi.org/10.1182/blood-2020-143253","mag":"3096239751"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-143253","doi":"https://doi.org/10.1182/blood-2020-143253","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-143253","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5007153916","display_name":"Tylan Magnusson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tylan Magnusson","raw_affiliation_strings":["University of Alabama at Birmingham, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama at Birmingham, Birmingham, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021580400","display_name":"Greer Burkholder","orcid":"https://orcid.org/0000-0001-7185-3025","observed_orcids":["https://orcid.org/0000-0001-7185-3025"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Greer Burkholder","raw_affiliation_strings":["University of Alabama at Birmingham, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama at Birmingham, Birmingham, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061978478","display_name":"Nathan B. Erdmann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nathan Erdmann","raw_affiliation_strings":["University of Alabama at Birmingham, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama at Birmingham, Birmingham, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030631799","display_name":"Amitkumar Mehta","orcid":"https://orcid.org/0000-0003-0537-4207","observed_orcids":["https://orcid.org/0000-0003-0537-4207"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amitkumar Mehta","raw_affiliation_strings":["University of Alabama at Birmingham, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama at Birmingham, Birmingham, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004490449","display_name":"Mayur Subhash Narkhede","orcid":"https://orcid.org/0000-0002-2606-0533","observed_orcids":["https://orcid.org/0000-0002-2606-0533"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mayur Narkhede","raw_affiliation_strings":["University of Alabama at Birmingham, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama at Birmingham, Birmingham, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5056210769","display_name":"Gaurav Goyal","orcid":"https://orcid.org/0000-0001-6148-5177","observed_orcids":["https://orcid.org/0000-0001-6148-5177"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gaurav Goyal","raw_affiliation_strings":["University of Alabama at Birmingham, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama at Birmingham, Birmingham, AL","institution_ids":["https://openalex.org/I32389192"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I32389192"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"136","issue":"Supplement 1","first_page":"20","last_page":"20"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":0.9789999723434448,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":0.9789999723434448,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0142000000923872,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12212","display_name":"CNS Lymphoma Diagnosis and Treatment","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hiv","display_name":"HIV","score":0.3630000054836273},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6359999775886536},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.8209999799728394},{"id":"https://openalex.org/keywords/african-american-patients","display_name":"African American patients","score":0.652999997138977},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.765999972820282},{"id":"https://openalex.org/keywords/r-chop","display_name":"R-CHOP","score":0.7829999923706055},{"id":"https://openalex.org/keywords/r-epoch","display_name":"R-EPOCH","score":0.8690000176429749},{"id":"https://openalex.org/keywords/cd4-count","display_name":"CD4 count","score":0.5809999704360962},{"id":"https://openalex.org/keywords/central-nervous-system-involvement","display_name":"central nervous system involvement","score":0.5799999833106995},{"id":"https://openalex.org/keywords/treatment-outcomes","display_name":"treatment outcomes","score":0.34200000762939453},{"id":"https://openalex.org/keywords/cd19","display_name":"CD19","score":0.40299999713897705},{"id":"https://openalex.org/keywords/cd30","display_name":"CD30","score":0.4569999873638153},{"id":"https://openalex.org/keywords/cd22","display_name":"CD22","score":0.39399999380111694}],"concepts":[{"id":"https://openalex.org/C2778559949","wikidata":"https://www.wikidata.org/wiki/Q2626074","display_name":"Diffuse large B-cell lymphoma","level":3,"score":0.8240566253662109},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7331215143203735},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.6485113501548767},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.643162727355957},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5660398602485657},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5419777631759644},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.4959658086299896},{"id":"https://openalex.org/C2780317896","wikidata":"https://www.wikidata.org/wiki/Q2703","display_name":"Epoch (astronomy)","level":3,"score":0.49295973777770996},{"id":"https://openalex.org/C144301174","wikidata":"https://www.wikidata.org/wiki/Q7893852","display_name":"Univariate analysis","level":3,"score":0.4711918830871582},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.4322836399078369},{"id":"https://openalex.org/C38180746","wikidata":"https://www.wikidata.org/wiki/Q1952580","display_name":"Multivariate analysis","level":2,"score":0.3033168911933899},{"id":"https://openalex.org/C1276947","wikidata":"https://www.wikidata.org/wiki/Q333","display_name":"Astronomy","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C150846664","wikidata":"https://www.wikidata.org/wiki/Q7602306","display_name":"Stars","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-143253","doi":"https://doi.org/10.1182/blood-2020-143253","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-143253","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2981142672","https://openalex.org/W7108636606","https://openalex.org/W3096077706","https://openalex.org/W4386271194","https://openalex.org/W7204685702","https://openalex.org/W7117902926","https://openalex.org/W2091791075","https://openalex.org/W2552646239","https://openalex.org/W3155025855","https://openalex.org/W3049596273"],"abstract_inverted_index":{"INTRODUCTION":[0],"Recent":[1],"studies":[2,136,149],"have":[3],"suggested":[4],"that":[5,32],"the":[6,55,161,201,319,347,390,494,584],"prognosis":[7],"of":[8,27,52,91,148,166,187,232,237,247,261,346,426,438,454,488,543,569,586,648,659,679,700],"HIV-associated":[9,570],"diffuse":[10],"large":[11],"B-cell":[12],"lymphoma":[13,233,470],"(HIV-DLBCL)":[14],"may":[15,34],"be":[16,35],"improving":[17],"with":[18,37,123,176,224,264,395,479,561,598,613,631],"advances":[19],"in":[20,54,95,107,152,266,330,397,501,522,593,610],"anti-retroviral":[21],"therapies":[22],"(ART).":[23],"A":[24,62],"pooled":[25],"analysis":[26,57,239],"clinical":[28,113,162],"trial":[29,87],"data":[30],"showed":[31,67,88],"EPOCH":[33],"associated":[36,394],"superior":[38],"outcomes":[39,151,165],"as":[40,111],"compared":[41],"to":[42,121,204,215,361,382,469,537,574],"CHOP":[43],"(Barta":[44],"et":[45,79,99],"al.":[46,80,100],"Blood.":[47],"2013),":[48],"but":[49],"about":[50],"two-third":[51],"patients":[53,77,117,168,220,263,288,335,370,419,483,505,511,526,541,557,596,611],"combined":[56],"were":[58,213,221,278,283,359,413,421,476,558],"treated":[59,76,193,369,377,597,612],"without":[60],"rituximab.":[61],"recent":[63],"French":[64],"study,":[65,158],"however,":[66],"similar":[68,89,573],"overall":[69,206],"survival":[70,207,400,568],"(OS)":[71],"between":[72,595],"R-CHOP":[73,92,368,599],"and":[74,83,128,143,164,173,192,210,230,245,280,292,356,452,473,564,633,642],"R-EPOCH":[75,94,376],"(Besson":[78],"AIDS":[81],"2017)":[82],"a":[84,138,146,184,259,605,628,634],"phase":[85],"III":[86],"efficacy":[90],"vs.":[93,373,499,600],"HIV-uninfected":[96],"DLBCL":[97,179,189,227,427,439,504,525,571],"(Bartlett":[98],"JCO":[101],"2019).":[102],"The":[103,300,364,490,567],"optimum":[104],"frontline":[105],"therapy":[106],"HIV-DLBCL":[108,167,219,265,556,578],"is":[109,145],"unknown":[110],"most":[112,134,555],"trials":[114],"exclude":[115],"HIV-infected":[116],"or":[118,249,403,661,681,702],"restrict":[119],"accrual":[120],"those":[122],"undetectable":[124],"HIV":[125,177,225],"viral":[126],"load":[127],"minimum":[129],"CD4":[130,302,644],"count":[131,303,434,645],"cut-off.":[132],"Moreover,":[133],"existing":[135],"include":[137],"majority":[139],"(>60%)":[140],"Caucasian":[141],"population,":[142],"there":[144,603],"paucity":[147],"on":[150,655,675,696],"African-American":[153],"population.":[154],"In":[155,552],"this":[156,380,587],"retrospective":[157,185],"we":[159,626],"describe":[160],"features":[163],"seen":[169,414],"at":[170,194,234,298,304,315,424,436,617,646],"our":[171,195,267,553],"institution":[172,196],"compare":[174],"them":[175],"negative":[178,226],"patients.":[180,333],"METHODS":[181],"We":[182,199,257],"conducted":[183,241],"review":[186],"HIV+":[188,510],"cases":[190],"diagnosed":[191],"from":[197,531],"2008-2020.":[198],"used":[200],"Kaplan-Meier":[202],"method":[203,244],"assess":[205,216],"(OS).":[208],"Univariate":[209],"multivariate":[211,388],"analyses":[212],"performed":[214],"prognostic":[217],"factors.":[218],"matched":[222,502,523],"1:2":[223],"by":[228],"age":[229,270],"stage":[231,290,563],"diagnosis.":[235,299,489,649],"Comparison":[236],"OS":[238,321,366,492,508,594,609],"was":[240,271,306,322,350,371,405,497,512,572,590,604,619],"using":[242,251],"log-rank":[243],"predictors":[246],"progression":[248,402],"death":[250],"Cox":[252],"proportional":[253],"hazards":[254],"regression.":[255],"RESULTS":[256],"included":[258,327],"total":[260],"33":[262],"study.":[268],"Median":[269,342,507],"46.6":[272],"years":[273,352,514,519],"(IQR":[274,308,353,515,520],"40-53.3),":[275],"25":[276,331],"(76%)":[277,332],"males,":[279],"20":[281],"(61%)":[282],"African-Americans":[284],"(Table).":[285],"28":[286],"(85%)":[287],"had":[289,295,312],"III/IV":[291],"24":[293],"(73%)":[294],"extranodal":[296,565],"disease":[297],"median":[301,320],"diagnosis":[305,428,440,618],"252":[307],"89.5-409).":[309],"6":[310],"(18%)":[311],"CNS":[313,615],"involvement":[314,616],"diagnosis,":[316,471],"for":[317,367,375,493,509],"which":[318],"8.3":[323],"months.":[324],"First-line":[325],"treatment":[326],"rituximab-chemotherapy":[328],"combinations":[329],"All":[334,577],"continued":[336,579],"ART":[337,466,580],"during":[338,545,581],"first":[339,547],"line":[340],"treatment.":[341,539],"follow":[343,362],"up":[344],"duration":[345],"entire":[348,495],"cohort":[349,496],"2.06":[351],"0.53-5.02":[354],"years)":[355],"5":[357],"(15.2%)":[358],"lost":[360],"up.":[363],"2-year":[365,491],"63%":[372],"38%":[374],"patients,":[378],"although":[379],"failed":[381],"reach":[383],"statistical":[384],"significance":[385],"(p=0.125).":[386],"On":[387],"analysis,":[389],"only":[391],"factor":[392],"significantly":[393],"difference":[396,592],"event":[398],"free":[399],"(EFS;":[401],"death)":[404],"female":[406],"sex":[407],"(HR":[408,429,441,448,458],"19.86;":[409],"[2.652-148.7];":[410],"p=0.004).":[411],"Trends":[412],"towards":[415,607],"shorter":[416],"EFS":[417],"among":[418],"who":[420],"tobacco":[422,640],"smokers":[423],"time":[425,437,647],"2.69;":[430],"0.463-15.6];":[431],"p=0.271),":[432],"CD4+":[433],"<200":[435],"2.39;":[442],"[0.519-11.0];":[443],"p=0.264),":[444],"IPI":[445],"score":[446],">3":[447],"2.98;":[449],"[0.480-18.5];":[450],"p=0.241),":[451],"presence":[453],"MYC":[455],"gene":[456],"rearrangement":[457],"3.93;":[459],"[0.569-27.2];":[460],"p=0.165).":[461],"Treatment":[462],"type":[463],"(R-CHOP,":[464],"R-EPOCH),":[465],"use":[467,641],"prior":[468,536],"race,":[472],"insurance":[474],"status":[475],"not":[477],"correlated":[478],"EFS.":[480],"11":[481],"(33.3%)":[482],"died":[484,530,542],"within":[485],"1":[486],"year":[487],"64%":[498],"68%":[500],"HIV-negative":[503,524,575],"(p=0.651).":[506],"2.14":[513],"0.23-5.77)":[516],"vs":[517],"2.97":[518],"0.76-6.48)":[521],"(p=0.3996).":[527],"One":[528],"patient":[529],"acute":[532],"hypoxemic":[533],"respiratory":[534],"failure":[535],"starting":[538],"Four":[540],"complications":[544],"their":[546],"inpatient":[548],"chemotherapy":[549],"administration.":[550],"CONCLUSION":[551],"cohort,":[554],"African-Americans,":[559],"presented":[560],"advanced":[562],"disease.":[566],"counterparts.":[576],"chemotherapy,":[582],"suggesting":[583],"feasibility":[585],"approach.":[588],"There":[589],"no":[591],"R-EPOCH,":[601],"however":[602],"trend":[606,635],"increased":[608],"R-CHOP.":[614],"frequently":[620],"seen.":[621],"Despite":[622],"limited":[623],"sample":[624],"size,":[625],"observed":[627],"significant":[629,637],"association":[630],"gender,":[632],"toward":[636],"factors":[638],"including":[639],"low":[643],"Disclosures":[650],"Mehta:":[651],"TG":[652],"Therapeutics:Consultancy,":[653],"Membership":[654,674,695],"an":[656,676,697],"entity's":[657,677,698],"Board":[658,678,699],"Directors":[660,680,701],"advisory":[662,682,703],"committees,":[663,683,704],"Research":[664,684,705],"Funding,":[665,685,706],"Speakers":[666,686,707],"Bureau;Merck:Research":[667],"Funding;Roche-Genentech:Research":[668],"Funding;Kite/Gilead:Research":[669],"Funding;Innate":[670],"Pharmaceuticals:Research":[671],"Funding;Seattle":[672],"Genetics:Consultancy,":[673],"Bureau;Oncotartis:Research":[687],"Funding;Gelgene/BMS:Research":[688],"Funding;Juno":[689],"Parmaceuticals/BMS:Research":[690],"Funding;fortyseven":[691],"Inc/Gilead:Research":[692],"Funding;Takeda:Research":[693],"Funding;Incyte:Consultancy,":[694],"Bureau;Affimed:Research":[708],"Funding.":[709]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1}],"updated_date":"2026-10-09T09:14:12.587421","created_date":"2020-11-09T00:00:00"}